Sector News

Stryker eyes deals, market share growth in Europe

January 15, 2015
Life sciences
(Reuters) – Orthopedic device and surgical equipment maker Stryker Corp said on Wednesday it is eyeing growth through acquisitions, and has set its sights on improving market share for its products in Europe.
 
Stryker Chief Executive Kevin Lobo, speaking at the JP Morgan healthcare conference in San Francisco, said the company was in a very strong cash position that would allow it to make acquisitions that are “small, medium or even large.”
 
“We need to be market leaders in the areas that we choose to play in,” Lobo said. “We’ll look at deals of all different sizes … to strengthen our position.”
 
Stryker plans to repatriate some $2 billion in cash held overseas in the second half of 2015.
 
The company on Tuesday cautioned that the strength of the U.S. dollar versus overseas currencies would take a larger than previously expected toll on 2015 earnings, shaving some 20 cents from per share profit versus its prior view of 10 to 12 cents.
 
Stryker currently has about two thirds of its total sales in the United States, with about a quarter coming from other developed markets and 8 percent from emerging markets.
 
Lobo sees Europe as a critical area with room for improving Stryker’s performance, and said he believes the capital spending climate there is improving.
 
“Our market shares are dramatically lower in Europe than in the U.S., Canada or Japan,” he said. “Our products should be garnering higher market share there.”
 
Stryker has altered its corporate structure so that operations in Europe will now report directly to the United States.
 
Despite the challenging environment in some emerging markets, such as Russia, Lobo said Stryker aims to increase its percentage of total sales from developing markets “to get to double digits in the next few years.”
 
Stryker shares were down $2.20, or 2.3 percent, at $92.02 on the New York Stock Exchange.
 
(Reporting by Bill Berkrot in New York; Editing by Bernard Orr)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”